【摘要】 目的评价非清髓性造血干细胞移植(NMSCT)的疗效及供受者嵌合体的检测。方法用氟达拉宾25mg/m2,-5d~-1d、马法兰140mg/m2?1d、抗胸腺细胞球蛋白15mg/(kg.d)-4d~+5d作为预处理方案,环胞霉素3mg/(kg.d),麦考芬酸脂15mg/(kg.d)用于GVHD的预防。为17例患者做了,并对嵌合体进行检测。结果17例患者达到了早期植入,中性粒细胞恢复至0.5×109/L,中位时间为13d,血小板恢复至30×109/L,中位时间为17d。全部供者粒细胞嵌合体形成中位时间为4周,全部供者T细胞形成中位时间为8周。结论应用氟达拉宾、马法兰、抗胸腺细胞球蛋白作为非清髓性造血干细胞移植预处理方案,可获得供者早期植入,不良反应少。更多还原

【Abstract】 Objective To evaluate the effect of non-myeloablative allo-genic stem cell transplantation (NMSCT)and test chimerism.Methods 17 patients have been done NMSCT with Fludarabine(25mg/m~2,-5d~-1d), Melphalan(140mg/m~2-1d) and ATG(15mg/(kg.d)-4d~+5d), condition regimen(cyclosporine 3mg/(kg.d) Myecophine 15mg/(kg.d) for GVHD prevention) and its chimerism have been tested. Results 17 patients were engrafted early. The median time to neutrophil 0.5×10~9/L and platelet 30×10~9/L was 13 and 17days post-transplant respectively. The median time to full donor myeloid cell and T cell chimerism was 4 and 8 weeks respectively. Conclusion Fludarabine melphalan and ATG as a conditioning regimen for NMSCT is safe and is engrafted early.更多还原